{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T18:12:03Z","timestamp":1785348723315,"version":"3.55.0"},"reference-count":62,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG055401"],"award-info":[{"award-number":["R01AG055401"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30AG043073"],"award-info":[{"award-number":["P30AG043073"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K01AG042498"],"award-info":[{"award-number":["K01AG042498"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL126804"],"award-info":[{"award-number":["R01HL126804"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL130462"],"award-info":[{"award-number":["R01HL130462"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Southern California Zumberge Research Fund","award":["1R34AG049652"],"award-info":[{"award-number":["1R34AG049652"]}]},{"name":"Schaeffer-Amgen Fellowship Program"},{"name":"Sigmund Gestetner Foundation"},{"name":"NIHR-EME"},{"DOI":"10.13039\/501100000320","name":"Alzheimer's Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000320","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Alzheimer's Research UK"},{"DOI":"10.13039\/100011699","name":"BRACE","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011699","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Research Council"},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01AG026572"],"award-info":[{"award-number":["P01AG026572"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0229541","type":"journal-article","created":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T18:33:55Z","timestamp":1583346835000},"page":"e0229541","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":52,"title":["Association of combination statin and antihypertensive therapy with reduced Alzheimer\u2019s disease and related dementia risk"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0511-5520","authenticated-orcid":true,"given":"Douglas","family":"Barthold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Diaz Brinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"Wharton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Gavin","family":"Kehoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Zissimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,3,4]]},"reference":[{"issue":"suppl_1","key":"pone.0229541.ref001","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1093\/geronb\/gbx147","article-title":"The impact of changes in population health and mortality on future prevalence of Alzheimer\u2019s disease and other dementias in the United States","volume":"73","author":"J.M. Zissimopoulos","year":"2018","journal-title":"The Journals of Gerontology: Series B"},{"key":"pone.0229541.ref002","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.trci.2018.08.009","article-title":"Racial and ethnic differences in trends in dementia prevalence and risk factors in the United States","volume":"4","author":"C. Chen","year":"2018","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"key":"pone.0229541.ref003","article-title":"Association of Lifestyle and Genetic Risk With Incidence of Dementia","author":"I. Lourida","year":"2019","journal-title":"JAMA"},{"key":"pone.0229541.ref004","volume-title":"Risk reduction of cognitive decline and dementia","author":"World Health Organization","year":"2019"},{"issue":"10113","key":"pone.0229541.ref005","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/S0140-6736(17)31363-6","article-title":"Dementia prevention, intervention, and care","volume":"390","author":"G. Livingston","year":"2017","journal-title":"The Lancet"},{"issue":"1","key":"pone.0229541.ref006","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1515\/fhep-2014-0013","article-title":"The Value of Delaying Alzheimer\u2019s Disease Onset","volume":"18","author":"J. Zissimopoulos","year":"2015","journal-title":"Forum for Health Economics and Policy"},{"issue":"5","key":"pone.0229541.ref007","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0002-9343(01)00870-1","article-title":"Clinically relevant differences between the statins: implications for therapeutic selection","volume":"111","author":"P.H. Chong","year":"2001","journal-title":"The American Journal of Medicine"},{"issue":"1","key":"pone.0229541.ref008","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jns.2009.02.352","article-title":"Therapeutic potential of statins in Alzheimer's disease","volume":"283","author":"N. Kandiah","year":"2009","journal-title":"Journal of the Neurological Sciences"},{"issue":"2","key":"pone.0229541.ref009","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamaneurol.2013.5390","article-title":"Low HDL and High LDL Serum Cholesterol Are Associated With Cerebral Amyloidosis","volume":"71","author":"B. Reed","year":"2014","journal-title":"JAMA Neurology"},{"issue":"3","key":"pone.0229541.ref010","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2174\/156720511795563755","article-title":"Cholesterol and LDL relate to neuritic plaques and to APOE4 presence but not to neurofibrillary tangles","volume":"8","author":"G. Lesser","year":"2011","journal-title":"Current Alzheimer Research"},{"issue":"1\u20132","key":"pone.0229541.ref011","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12031-002-0026-2","article-title":"Statin therapy for Alzheimer\u2019s disease","volume":"19","author":"S.S. Petanceska","year":"2002","journal-title":"Journal of Molecular Neuroscience"},{"issue":"5","key":"pone.0229541.ref012","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1006\/nbdi.2001.0422","article-title":"A cholesterol-lowering drug reduces \u03b2-amyloid pathology in a transgenic mouse model of Alzheimer's disease","volume":"8","author":"L.M. Refolo","year":"2001","journal-title":"Neurobiology of Disease"},{"issue":"10","key":"pone.0229541.ref013","doi-asserted-by":"crossref","first-page":"688","DOI":"10.7326\/0003-4819-159-10-201311190-00007","article-title":"Statins and cognitive function: a systematic review","volume":"159","author":"K. Richardson","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"11","key":"pone.0229541.ref014","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1001\/archneurol.2011.242","article-title":"Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations","volume":"68","author":"N.E. Shepardson","year":"2011","journal-title":"Archives of Neurology"},{"issue":"1","key":"pone.0229541.ref015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40035-018-0110-3","article-title":"The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms","volume":"7","author":"B.G. Schultz","year":"2018","journal-title":"Translational Neurodegeneration"},{"issue":"2","key":"pone.0229541.ref016","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamaneurol.2016.3783","article-title":"Sex and Race Differences in the Association Between Statin Use and the Incidence of Alzheimer Disease","volume":"74","author":"J.M. Zissimopoulos","year":"2017","journal-title":"JAMA Neurology"},{"key":"pone.0229541.ref017","article-title":"Association Between Statin Use and Risk of Dementia After a Concussion","author":"D.A. Redelmeier","year":"2019","journal-title":"JAMA Neurology"},{"issue":"1","key":"pone.0229541.ref018","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/jnnp.2008.150433","article-title":"Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study","volume":"80","author":"M.D. Haag","year":"2009","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"9242","key":"pone.0229541.ref019","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(00)03155-X","article-title":"Statins and the risk of dementia","volume":"356","author":"H. Jick","year":"2000","journal-title":"The Lancet"},{"issue":"7","key":"pone.0229541.ref020","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/j.1532-5415.2010.02906.x","article-title":"Age\u2010Varying Association Between Statin Use and Incident Alzheimer's Disease","volume":"58","author":"G. Li","year":"2010","journal-title":"Journal of the American Geriatrics Society"},{"issue":"47","key":"pone.0229541.ref021","doi-asserted-by":"crossref","first-page":"e2143","DOI":"10.1097\/MD.0000000000002143","article-title":"Early Statin Use and the Progression of Alzheimer Disease: A Total Population-Based Case-Control Study","volume":"94","author":"F.-C. Lin","year":"2015","journal-title":"Medicine"},{"issue":"1","key":"pone.0229541.ref022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1741-7015-5-20","article-title":"Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease","volume":"5","author":"B. Wolozin","year":"2007","journal-title":"BMC Medicine"},{"issue":"1","key":"pone.0229541.ref023","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13195-017-0237-y","article-title":"Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer\u2019s disease","volume":"9","author":"N. Geifman","year":"2017","journal-title":"Alzheimer's Research & Therapy"},{"issue":"1","key":"pone.0229541.ref024","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13195-017-0332-0","article-title":"Data-driven identification of endophenotypes of Alzheimer\u2019s disease progression: implications for clinical trials and therapeutic interventions","volume":"10","author":"N. Geifman","year":"2018","journal-title":"Alzheimer's Research & Therapy"},{"issue":"12","key":"pone.0229541.ref025","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1212\/WNL.0000000000004392","article-title":"Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults","volume":"89","author":"G. Li","year":"2017","journal-title":"Neurology"},{"issue":"9","key":"pone.0229541.ref026","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1212\/01.wnl.0000277657.95487.1c","article-title":"Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease","volume":"69","author":"G. Li","year":"2007","journal-title":"Neurology"},{"issue":"2","key":"pone.0229541.ref027","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40263-015-0230-6","article-title":"Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms","volume":"29","author":"L. Rouch","year":"2015","journal-title":"CNS Drugs"},{"issue":"6","key":"pone.0229541.ref028","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/HJH.0b013e3283603f53","article-title":"Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis","volume":"31","author":"N.L. Marpillat","year":"2013","journal-title":"Journal of Hypertension"},{"issue":"8","key":"pone.0229541.ref029","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1474-4422(08)70143-1","article-title":"Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial","volume":"7","author":"R. Peters","year":"2008","journal-title":"The Lancet Neurology"},{"issue":"10046","key":"pone.0229541.ref030","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(16)30950-3","article-title":"Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial","volume":"388","author":"E.P.M. van Charante","year":"2016","journal-title":"The Lancet"},{"issue":"2","key":"pone.0229541.ref031","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2990.2007.00885.x","article-title":"Angiotensin\u2010converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE\u20101 to cerebral amyloid angiopathy","volume":"34","author":"J. Miners","year":"2008","journal-title":"Neuropathology and Applied Neurobiology"},{"issue":"2","key":"pone.0229541.ref032","first-page":"163","article-title":"Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes","volume":"1","author":"S. Miners","year":"2009","journal-title":"American Journal of Translational Research"},{"issue":"11","key":"pone.0229541.ref033","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1097\/NEN.0b013e3182345e46","article-title":"A\u03b2-degrading enzymes: potential for treatment of Alzheimer disease","volume":"70","author":"J.S. Miners","year":"2011","journal-title":"Journal of Neuropathology & Experimental Neurology"},{"issue":"1","key":"pone.0229541.ref034","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13195-016-0217-7","article-title":"Angiotensin-converting enzyme 2 is reduced in Alzheimer\u2019s disease in association with increasing amyloid-\u03b2 and tau pathology","volume":"8","author":"P.G. Kehoe","year":"2016","journal-title":"Alzheimer's Research & Therapy"},{"issue":"3","key":"pone.0229541.ref035","doi-asserted-by":"crossref","DOI":"10.3233\/JAD-171119","article-title":"The coming of age of the angiotensin hypothesis in Alzheimer's disease\u2013progress towards disease prevention and treatment?","volume":"62","author":"P.G. Kehoe","year":"2018","journal-title":"Journal of Alzheimer's Disease"},{"issue":"4","key":"pone.0229541.ref036","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1474-4422(07)70077-7","article-title":"Is inhibition of the renin\u2013angiotensin system a new treatment option for Alzheimer's disease?","volume":"6","author":"P.G. Kehoe","year":"2007","journal-title":"The Lancet Neurology"},{"issue":"12","key":"pone.0229541.ref037","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.tins.2009.07.006","article-title":"Angiotensins in Alzheimer's disease\u2013friend or foe?","volume":"32","author":"P.G. Kehoe","year":"2009","journal-title":"Trends in Neurosciences"},{"key":"pone.0229541.ref038","first-page":"1","article-title":"Neurofibrillary Tangles and Conversion to Mild Cognitive Impairment with Certain Antihypertensives","author":"W. Wharton","year":"2019","journal-title":"Journal of Alzheimer's Disease"},{"issue":"9","key":"pone.0229541.ref039","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/jgs.13627","article-title":"Modulation of Renin\u2010Angiotensin System May Slow Conversion from Mild Cognitive Impairment to Alzheimer's Disease","volume":"63","author":"W. Wharton","year":"2015","journal-title":"Journal of the American Geriatrics Society"},{"issue":"12","key":"pone.0229541.ref040","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1001\/archneurol.2012.1010","article-title":"Impact of Angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series","volume":"69","author":"I. Hajjar","year":"2012","journal-title":"Archives of Neurology"},{"issue":"2","key":"pone.0229541.ref041","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/jgs.12100","article-title":"Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial","volume":"61","author":"I. Hajjar","year":"2013","journal-title":"Journal of the American Geriatrics Society"},{"key":"pone.0229541.ref042","doi-asserted-by":"crossref","first-page":"b5465","DOI":"10.1136\/bmj.b5465","article-title":"Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis","volume":"340","author":"N.-C. Li","year":"2010","journal-title":"BMJ"},{"issue":"7","key":"pone.0229541.ref043","doi-asserted-by":"crossref","first-page":"P1659","DOI":"10.1016\/j.jalz.2018.06.3029","article-title":"Exploring ACE-2 as a novel therapeutic target for Alzheimer's disease","volume":"14","author":"C.E. Evans","year":"2018","journal-title":"Alzheimer's & Dementia: The Journal of the Alzheimer's Association"},{"issue":"11","key":"pone.0229541.ref044","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206705","article-title":"The association of multiple anti-hypertensive medication classes with Alzheimer\u2019s disease incidence across sex, race, and ethnicity","volume":"13","author":"D. Barthold","year":"2018","journal-title":"PLOS ONE"},{"issue":"22","key":"pone.0229541.ref045","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1056\/NEJMhpr1804089","article-title":"Medicare Advantage Checkup","volume":"379","author":"P. Neuman","year":"2018","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"pone.0229541.ref046","first-page":"1","article-title":"Comparison of the performance of the CMS Hierarchical Condition Category (CMS-HCC) risk adjuster with the Charlson and Elixhauser comorbidity measures in predicting mortality","volume":"10","author":"P. Li","year":"2010","journal-title":"BMC Health Services Research"},{"key":"pone.0229541.ref047","volume-title":"Creation of new race-ethnicity codes and socioeconomic status (SES) indicators for Medicare beneficiaries","author":"A. Bonito","year":"2008"},{"key":"pone.0229541.ref048","volume-title":"Medicines use and spending in the US: a review of 2016 and outlook to 2021","author":"M. Aitken","year":"2016"},{"key":"pone.0229541.ref049","volume-title":"Association for Accesible Medicines","author":"D. Long","year":"2018"},{"key":"pone.0229541.ref050","article-title":"Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease","volume":"6","author":"A. Luvai","year":"2012","journal-title":"Clinical Medicine Insights: Cardiology"},{"issue":"9","key":"pone.0229541.ref051","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1177\/009127002401102876","article-title":"A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin","volume":"42","author":"C.M. White","year":"2002","journal-title":"The Journal of Clinical Pharmacology"},{"issue":"2","key":"pone.0229541.ref052","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.amjcard.2005.08.026","article-title":"Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial","volume":"97","author":"K.C. Ferdinand","year":"2006","journal-title":"The American Journal of Cardiology"},{"key":"pone.0229541.ref053","unstructured":"Flockhart, D.A. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine 2007 September 1, 2019]; Available from: https:\/\/drug-interactions.medicine.iu.edu"},{"issue":"1","key":"pone.0229541.ref054","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1212\/NXG.0000000000000216","article-title":"CYP2C19 variant mitigates Alzheimer disease pathophysiology in vivo and postmortem","volume":"4","author":"A.L. Benedet","year":"2018","journal-title":"Neurology Genetics"},{"key":"pone.0229541.ref055","unstructured":"ALZGENE. Chromosome 10: Location of Published AD Candidate Genes. 2019 September 1, 2019]; Available from: http:\/\/www.alzgene.org\/chromo.asp?c=10"},{"issue":"4","key":"pone.0229541.ref056","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/tpj.2010.28","article-title":"Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs","volume":"11","author":"D. Wang","year":"2011","journal-title":"The Pharmacogenomics Journal"},{"issue":"3","key":"pone.0229541.ref057","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1517\/17425255.2012.657626","article-title":"Cytochrome P450 variations in different ethnic populations","volume":"8","author":"J. McGraw","year":"2012","journal-title":"Expert opinion on drug metabolism & toxicology"},{"issue":"2","key":"pone.0229541.ref058","first-page":"173","article-title":"Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver","volume":"27","author":"W. Jacobsen","year":"1999","journal-title":"Drug Metabolism and Disposition"},{"issue":"6","key":"pone.0229541.ref059","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.bbadis.2016.03.001","article-title":"Graded perturbations of metabolism in multiple regions of human brain in Alzheimer's disease: Snapshot of a pervasive metabolic disorder","volume":"1862","author":"J. Xu","year":"2016","journal-title":"Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease"},{"issue":"7","key":"pone.0229541.ref060","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1161\/01.CIR.0000139312.10076.BA","article-title":"Update on statins: 2003","volume":"110","author":"C.J. Vaughan","year":"2004","journal-title":"Circulation"},{"key":"pone.0229541.ref061","doi-asserted-by":"crossref","unstructured":"Deane, R., et al., Clearance of amyloid-\u03b2 peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders), 2009. 8(1): p. 16\u201330.","DOI":"10.2174\/187152709787601867"},{"issue":"6","key":"pone.0229541.ref062","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jama.2019.10551","article-title":"Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter Lesions","volume":"322","author":"I.M. Nasrallah","year":"2019","journal-title":"JAMA"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0229541","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T14:13:34Z","timestamp":1614694414000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0229541"}},"subtitle":[],"editor":[{"given":"Tarek K.","family":"Rajji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,3,4]]},"references-count":62,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0229541","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,4]]}}}